|
|
|
| The interaction of Clopidogrel with SSRIs mediated by CYP2C19 |
| FAN Youmin1 MA Xiuping2 CHEN Songjie1 GENG Deqin2▲ |
1.Clinical College, Xuzhou Medical University, Jiangsu Province, Xuzhou 221000, China;
2.Department of Neurology, Affiliated Hospital of Xuzhou Medical University, Jiangsu Province, Xuzhou 221000, China |
|
|
|
Abstract Along with the general rising of the incidence of post-stroke depression, selective serotonin reuptake inhibitors (SSRI) and dual anti-platelet therapy are widely used for patients with post-stroke depression in clinic. However, both SSRI and Clopidogrel are metabolized by hepatocyte pigment P450 isoenzyme system, some meta-analysis and small sample researches indicate that SSRI can reduce the anti-platelet effects of Clopidogrel by inhibiting the activity of hepatocyte pigment P450 isoenzyme CYP2C19. According to the different chemical structures and pharmacokinetic characteristics of SSRIs, the degrees of suppression of SSRI are not alike. This article summaries the drug metabolism pathway, mechanism and clinical research progress of this two drugs.
|
|
|
|
|
|
[1] Xu XM，Zou DZ，Shen LY，et al. Efficacy and feasibility of antidepressant treatment in patients with post-stroke depression [J]. Medicine（Baltimore），2016，95（45）：e5349.
[2] Shen X，Liu M，Cheng Y，et al. Repetitive transcranial magnetic stimulation for the treatment of post-stroke depression：A systematic review and meta-analysis of randomized controlled clinical trials [J]. J Affect Disord，2017， 211：65-74.
[3] Treuer T，Liu CY，Salazar G，et al. Use of antidepressants in the treatment of depression in Asia：guidelines，clinical evidence，and experience revisited [J]. Asia Pac Psychiatry，2013，5（4）：219-230.
[4] Zhou SF，Liu JP，Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact [J]. Drug Metab Rev，2009，41（2）：89-295.
[5] Sim SC，Risinger C，Dahl ML，et al. A common novel CYP 2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants [J]. Clin Pharmacol Ther，2006，79（1）：103-113.
[6] Yang Y，Lewis JP，Hulot JS，et al. The pharmacogenetic control of antiplatelet response：candidate genes and CYP2C19 [J]. Expert Opin Drug Metab Toxicol，2015，11（10）：1599-1617.
[7] Yi X，Wang Y，Lin J，et al. Interaction of CYP2C19，P2Y12，and GPⅢa Variants Associates With Efficacy of Clopidogrel and Adverse Events on Patients With Ischemic Stroke [J]. Clin Appl Thromb Hemost，2017，23（7）：761-768.
[8] Hulot JS，Collet JP，Silvain J，et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration：a systematic meta-analysis [J]. J Am Coll Cardiol，2010，56（2）：134-143.
[9] Ornoy A，Koren G. Selective Serotonin Reuptake Inhibitors during Pregnancy：Do We Have Now More Definite Answers Related to Prenatal Exposure [J]. Birth Defects Res，2017，109（12）：898-908.
[10] Hicks JK，Bishop JR，Sangkuhl K，et al. Clinical Pharmacogenetics Implementation Consortium（CPIC）Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors [J]. Clin Pharmacol Ther，2015，98（2）：127-134.
[11] Scordo MG，Spina E，Dahl ML，et al. Influence of CYP 2C9，2C19 and 2D6 genetic polymorphisms on the steady-state plasma concentrations of the enantiomers of fluoxetine and norfluoxetine [J]. Basic Clin Pharmacol Toxicol，2005，97（5）：296-301.
[12] Sager JE，Lutz JD，Foti RS，et al. Fluoxetine- and norfluoxetine-mediated complex drug-drug interactions：in vitro to in vivo correlation of effects on CYP2D6，CYP2C19，and CYP3A4 [J]. Clin Pharmacol Ther，2014， 95（6）：653-662.
[13] Delavenne X，Magnin M，Basset T，et al. Investigation of drug-drug interactions between clopidogrel and fluoxetine [J]. Fundam Clin Pharmacol，2013，27（6）：683-689.
[14] Hiemke C，Baumann P，Bergemann N，et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry：update 2011 [J]. Pharmacopsychiatry，2011，44（6）：195-235.
[15] Uno T，Shimizu M，Yasui-Furukori N，et al. Different effects of fluvoxamine on rabeprazole pharmacokinetics in relation to CYP2C19 genotype status [J]. Br J Clin Pharmacol，2006，61（3）：309-314.
[16] Chen F，Yang Y，Fang C，et al. Effect of fluvoxamine on the pharmacokinetics and pharmacodynamics of clopidogrel in rats [J]. Xenobiotica，2015，45（12）：1122-1128.
[17] Kumar Y，Kung S，Shinozaki G. CYP2C19 variation，not citalopram dose nor serum level，is associated with QTc prolongation [J]. J Psychopharmacol，2014，28（12）：1143-1148.
[18] Br?覬sen K，Naranjo CA. Review of pharmacokinetic and pharmacodynamic interaction studies with citalopram [J]. Eur Neuropsychopharmacol，2001，11（4）：275-283.
[19] Chang M，Tybring G，Dahl ML，et al. Impact of cytochrome P450 2C19 polymorphisms on citalopram/escitalopram exposure：a systematic review and meta-analysis [J]. Clin Pharmacokinet，2014，53（9）：801-811.
[20] Jornil J，Jensen KG，Larsen F，et al. Identification of cytochrome P450 isoforms involved in the metabolism of paroxetine and estimation of their importance for human paroxetine metabolism using a population-based simulator [J]. Drug Metab Dispos，2010，38（3）：376-385.
[21] Jeppesen U，Gram LF，Vistisen K，et al. Dose-dependent inhibition of CYP1A2，CYP2C19 and CYP2D6 by citalopram，fluoxetine，fluvoxamine and paroxetine [J]. Eur J Clin Pharmacol，1996，51（1）：73-78.
[22] Rudberg I，Hermann M，Refsum H，et al. Serum concentrations of sertraline and N-desmethyl sertraline in relation to CYP2C19 genotype in psychiatric patients [J]. Eur J Clin Pharmacol，2008，64（12）：1181-1188.
[23] Wang JH，Liu ZQ，Wang W，et al. Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19 [J]. Clin Pharmacol Ther，2001，70（1）：42-47.
[24] Kobayashi K，Ishizuka T，Shimada N，et al. Sertraline N-demethylation is catalyzed by multiple isoforms of human cytochrome P-450 in vitro [J]. Drug Metab Dispos，1999， 27（7）：763-766.
[25] DeVane CL，Liston HL，Markowitz JS. Clinical pharmacokinetics of sertraline [J]. Clin Pharmacokinet，2002，41（15）：1247-1266. |
|
|
|
